Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.69 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | ACACA | Q13085 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851450 | 0.97 | HRH3 (0.65) | HRH3PROKR1 | |
| SCHEMBL2846835 | 0.91 | HRH3 (0.56) | HRH3PROKR1KDM4E | |
| SCHEMBL2850958 | 0.87 | HRH3 (0.65) | HRH3PROKR1ACACBACACA | |
| SCHEMBL2845067 | 0.87 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2848874 | 0.85 | HRH3 (0.81) | HRH3KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL2841299 | 0.83 | HRH3 (0.64) | HRH3PROKR1 | |
| SCHEMBL601372 | 0.83 | PROKR1 (0.52) | HRH3PROKR1KDM4E | |
| SCHEMBL2852760 | 0.83 | HRH3 (0.61) | HRH3 | |
| SCHEMBL2848031 | 0.82 | HRH3 (0.67) | HRH3KDM4EACACBACACAL3MBTL3 | |
| SCHEMBL2851223 | 0.82 | HRH3 (0.76) | HRH3KDM4EL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | claimed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885PROKR1 361/4885KDM4E 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.